Travere Therapeutics (NASDAQ:TVTX) CAO Sells $139,175.96 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 4,333 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $32.12, for a total value of $139,175.96. Following the sale, the chief accounting officer directly owned 49,080 shares in the company, valued at $1,576,449.60. This represents a 8.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, December 24th, Sandra Calvin sold 7,402 shares of Travere Therapeutics stock. The shares were sold at an average price of $40.00, for a total value of $296,080.00.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $29.47 on Friday. The stock’s 50-day moving average is $33.88 and its two-hundred day moving average is $27.80. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. Travere Therapeutics, Inc. has a 1-year low of $12.91 and a 1-year high of $42.13. The company has a market cap of $2.64 billion, a price-to-earnings ratio of -27.80, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Several research firms have commented on TVTX. TD Cowen reiterated a “buy” rating on shares of Travere Therapeutics in a report on Friday, October 31st. HC Wainwright reiterated a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a research note on Friday, November 28th. Citigroup increased their target price on Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a report on Friday, October 31st. Guggenheim reaffirmed a “buy” rating and set a $49.00 price objective on shares of Travere Therapeutics in a research report on Wednesday, January 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $38.86.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently made changes to their positions in TVTX. Vanguard Group Inc. lifted its holdings in shares of Travere Therapeutics by 10.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,613,368 shares of the company’s stock valued at $158,059,000 after purchasing an additional 619,085 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Travere Therapeutics by 27.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock worth $41,203,000 after buying an additional 599,102 shares during the period. Emerald Advisers LLC lifted its stake in Travere Therapeutics by 2.6% in the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock valued at $51,308,000 after buying an additional 55,407 shares during the last quarter. Geode Capital Management LLC lifted its stake in Travere Therapeutics by 1.4% in the second quarter. Geode Capital Management LLC now owns 2,003,701 shares of the company’s stock valued at $29,658,000 after buying an additional 27,040 shares during the last quarter. Finally, Stephens Investment Management Group LLC boosted its holdings in shares of Travere Therapeutics by 7.6% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,721,623 shares of the company’s stock valued at $65,783,000 after acquiring an additional 121,955 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.